SUNRISE, FL – March 20, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, is pleased to announce its Chief Science Officer, Dr. Kristin Comella, has accepted an invitation to present at the 2018 Paleo f(x) Ancestral Healing Conference Friday, April 27, at the Palmer Events Center in Austin, Texas.
Dr. Comella will present “Regenerative Medicine: The Future of Medicine is Here,” at 4:25 p.m. CST at the Kegenix Paleo On Ramp Stage. Her presentation will be livestreamed on the USRM facebook page, follow to receive a live notification.
Dr. Comella will also participate in a Mastermind Panel entitled “Alt-Med: New Paradigms in Health and Wellness,” with several other world leaders in innovative health, including Dr. Joseph Mercola, Neurologist Dr. David Perlmutter, Naturopath Dr. Harry Adelson, epigenetic pioneer Dr. Ben Lynch and functional medicine expert Dr. Michael Ruscio, on Friday, April 27 at 5:35 p.m. CST at the ID LifeWellness Keynote Stage. The topic will explore how traditional western medicine has been undeniably successful in battling communicable diseases and acute trauma, but how do we navigate its failure to deal with the diseases of modernity that plague us now?
“I am honored to have the opportunity to participate in the Paleo f(x) conference with such esteemed colleagues, and to share with the audience and other world innovators our latest developments on autologous stem cell therapy and stromal vascular fraction,” said Dr. Comella. “It will be a pleasure to participate in this conference, which will feature a very interesting presence of leading health practitioners from around the world.”
Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM’s proprietary AdipocellTM product, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells.
Once harvested, through a minimally invasive liposuction procedure that is performed while the patient is comfortable but fully awake, the stem cells are then re-injected intravenously or applied directly to a damaged tissue for a more targeted application.
In January, the Company announced AdipocellTM reached sales of 10,000+ kits worldwide.
Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration. Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.
USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.